Pancreatic Cancer Gene Therapy: From Molecular Targets to Delivery Systems

Cancers

Cristina Fillat¹  Anabel Jose²  Xavier Bofill-De Ros²  Ana Mato-Berciano²  Maria Victoria Maliandi² 

[1] Programa Gens i Malaltia, Centre de Regulació Genòmica-CRG, UPF, Parc de Recerca Biomedica de Barcelona-PRBB and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain;

关键词: viral and non-viral vectors;    oncolysis;    gene delivery routes;    clinical trials;   

DOI  :  10.3390/cancers3010368

来源: mdpi

【 摘 要 】

The continuous identification of molecular changes deregulating critical pathways in pancreatic tumor cells provides us with a large number of novel candidates to engineer gene-targeted approaches for pancreatic cancer treatment. Targets—both protein coding and non-coding—are being exploited in gene therapy to influence the deregulated pathways to facilitate cytotoxicity, enhance the immune response or sensitize to current treatments. Delivery vehicles based on viral or non-viral systems as well as cellular vectors with tumor homing characteristics are a critical part of the design of gene therapy strategies. The different behavior of tumoral versus non-tumoral cells inspires vector engineering with the generation of tumor selective products that can prevent potential toxic-associated effects. In the current review, a detailed analysis of the different targets, the delivery vectors, the preclinical approaches and a descriptive update on the conducted clinical trials are presented. Moreover, future possibilities in pancreatic cancer treatment by gene therapy strategies are discussed.

【 授权许可】

CC BY   
© 2011 by the authors; licensee MDPI, Basel, Switzerland.